title: Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
authors.affiliation: Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Jacobus
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: S V
authors.initials: SV
authors.lastname: Rajkumar
authors.affiliation: ThedaCare, Appleton, WI, USA.
authors.forename: M
authors.initials: M
authors.lastname: Weiss
authors.affiliation: Mayo Clinic in Arizona, Scottsdale, AZ, South Africa.
authors.forename: A K
authors.initials: AK
authors.lastname: Stewart
authors.affiliation: University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Stadtmauer
authors.affiliation: University of Wisconsin, Madison, WI, USA.
authors.forename: N S
authors.initials: NS
authors.lastname: Callander
authors.affiliation: University of Pretoria, Pretoria, South Africa.
authors.forename: L M
authors.initials: LM
authors.lastname: Dreosti
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: M Q
authors.initials: MQ
authors.lastname: Lacy
authors.affiliation: Mayo Clinic in Arizona, Scottsdale, AZ, South Africa.
authors.forename: R
authors.initials: R
authors.lastname: Fonseca
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage* / Q000009:adverse effects; D060830:Consolidation Chemotherapy / Q000009:adverse effects / Q000379:methods; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016879:Salvage Therapy; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide